share_log

Mizuho Reiterates Neutral on Nektar Therapeutics, Maintains $6 Price Target

Benzinga ·  Aug 7, 2023 11:30

Mizuho analyst Mara Goldstein reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and maintains $6 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment